Latest Peplin news
09-June-09
Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more
28-May-09
Peplin's Positive Phase II AK Trial Results Published in JAAD read more
17-May-09
Positive Results for Peplin's First Phase III AK Trial read more
15-May-09
Peplin Results for the Quarter Ended 31 March 2009 read more
Glossary
Source: Modified from Medline Plus
| cell proliferation | Increase in the number of cells as a result of cell division |
| chemotherapy | The use of chemical agents in the treatment or control of disease or mental disorders |
| clinical trials | Medical research studies conducted on human subjects to answer scientific questions and to find better ways to prevent, detect or treat diseases |
| efficacy | The ability of a drug to control or cure an illness or disease |
| FDA | Food and Drug Administration |
| formulation | Incorporation of a drug into a relevant delivery vehicle, such as a gel |
| GMP | Good Manufacturing Process |
| intravenous (IV) | Situated within, performed within, occurring within, or administered by entering a vein - injection of a drug into the bloodstream through a vein |
| intra-cavitary (IC) | Situated or occurring within a body cavity (i.e. treatment characterized by the insertion of substances in a cavity) |
| IND | Investigational new drug |
| kinase | An enzyme that catalyzes the transfer of phosphate groups from a high-energy phosphate-containing molecule (as ATP or ADP) to a substrate |
| malignant | Cancerous - of unfavorable prognosis |
| melanocytes | An epidermal cell that produces melanin |
| metastases, metastasise | Transfer of a disease-producing agency (e.g. cancer cells) from an original site of disease to another part of the body with development of a similar lesion in a new location |
| mutation | A relatively permanent change in hereditary material (gene) involving a physical change in chromosome relations |
| pathway | A system of proteins that work together |
| pharmacokinetics | The study of the bodily absorption, distribution, metabolism and excretion of drugs |
| pharmacology | Evaluation of the activity of the drug in various cell systems and animal models of the disease |
| phase I | Clinical trial designed to determine the safety and appropriate dose |
| phase II | Clinical trial designed to measure the safety and efficacy |
| phase III | Clinical trial designed to test new treatment and measure efficacy as well as safety as compared to the standard of care |
| progression | A trend or shift toward a high, more severe state - increase of tumour size (opposite of regression) |
| receptor | A chemical group or molecule (as a protein) on the cell surface or in the cell interior that has an affinity for a specific chemical group, molecule, or virus |
| regimen | A systematic plan designed to improve and maintain the health of a patient |
| regression | A trend or shift toward a lower, less severe or less perfect state - reduction in the size of tumour (opposite of progression) |
| therapeutic | Of or relating to the treatment of disease or disorders by remedial agents or methods |
| therapy (therapies) | Treatment(s) |
| toxicity | The quality, state, or relative degree of being toxic or poisonous |
| toxicology | Evaluation of the safety profile of a drug |
| tumour | An abnormal benign or malignant mass of tissue that is not inflammatory, arises without obvious cause from cells of preexistent tissue, and possesses no physiological function |